A 29-year-old man with schizophrenia treated with aripiprazole 15 mg/d visited his
psychiatrist accompanied by his mother, who mentioned that although her son is doing well …

The recent publication by Salzman et al1 compared pharmacokinetic (PK) data from
population PK (popPK) models for two long-acting antipsychotic formulations: aripiprazole …

I n this issue, Kane and colleagues 1 report on the efficacy of aripiprazole long-acting
injection (LAI) in the treatment of an acute episode of schizophrenia. At 10 weeks of …

As long-acting injectable antipsychotic administration intervals widen, pharmacokinetic (PK)
profiles help facilitate an understanding of drug exposures achieved. Aripiprazole lauroxil …

Background Aripiprazole lauroxil is an extended-release prodrug of aripiprazole for
intramuscular injection, approved for schizophrenia treatment. We developed a population …

To the Editors: Approximately 4% to 30% of schizo-phrenic patients have comorbidity related
to stimulant use disorder (eg, amphetamines). 1 Stimulant exposure may worsen existing …

To the Editor: In a comprehensive and elegant review on long-acting injectable
antipsychotics (LAIs) published in a recent supplement to the Journal, Correll et al reported …

We read with interest Dr. VandenBerg's Psychopharmacology Pearl article1 in the October
2022 issue of Mental Health Clinician discussing recently approved long-acting injectable …

Sir: Aripiprazole is a new antipsychotic that works as a partial agonist/antagonist at
dopamine D 2 and serotonin 5-HT 1A receptors and has a favorable side effect profile. 1 The …

IntroductionDespite the widespread use of long-acting injectable (LAI) antipsychotics in
schizophrenia and other disorders, there is a lack of longitudinal studies evaluating …